Chevron's earnings rose sharply
On January 27, Chevron released its financial statements for the fourth quarter and the whole year of 2022. The financial report showed that the company's revenue in the fourth quarter of 2022 was $6.4 billion, compared with $5.1 billion in the fourth quarter of 2021. The income of $6.4 billion includes international upstream write-off and impairment charges of $1.1 billion and pension settlement costs of $17 million. The impact of foreign exchange reduced revenue by $405 million. The adjusted company income in the fourth quarter of 2022 was $7.9 billion, while the adjusted income in the fourth quarter of 2021 was $4.9 billion. The sales and other operating revenue in the fourth quarter of 2022 was $55 billion, compared with $46 billion in the same period last year.
Chevron reported that the annual revenue in 2022 was US $35.5 billion, compared with US $15.6 billion in 2021. The adjusted income in 2022 was $36.5 billion, while the adjusted income in 2021 was $15.6 billion. However, the company's total profit in 2022 and fourth quarter earnings were lower than Wall Street's expectations, mainly affected by asset write-downs and the decline in oil and gas prices.
LG Chemical has a net loss
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Chevron Opens Oilfield Chemical Technology to Rivals
-
The two major American oil companies shrink their global layout
-
Chevron Phillips 1-hexene project started
-
Chevron acquires Nobel Energy
-
Chevron Lummus Global announces technology award for IOC's Haldia refinery
-
As Middle East Supply Faces Disruptions, SABIC's 1.8 Million Mt/Year Methanol New Project Secures Saudi Feedstock Quota
-
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
Novo Nordisk’s Oral Wegovy Wins EU Approval as Weight-Loss Competition Shifts from Injections to Pills
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
Recommend Reading
-
Fracturing the Crown: BASF Antwerp’s 600-Job Cut and the Global Alarm
-
Wanhua Chemical and Xingfa Group Jointly Develop 5.32 Billion Yuan Phosphate Mine
-
Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market
-
$1.35 Billion! AkzoNobel to Sell Decorative Paints Business in Southeast Asia and Australia to Nippon Paint
-
Nylon Giant to Close Another European Plant, Cutting 140 Jobs
-
Business Society’s September 9, 2026 View on Isooctanol Market Trends: Clearly Downward
-
Business Society’s DOP Market Outlook on August 20, 2026: Clearly Upward
-
Focusing on Cost Reduction! Rubber Industry Chain Prices Overall Upward in Early September
-
Business Society’s Market Outlook for Maleic Anhydride on August 19, 2026: Volatile
-
Business Society’s Market Outlook for Styrene Butadiene Rubber on September 9, 2026: Spot Prices Fluctuate at High Levels
- Hot Searches
- sterioids for sale
- where can i buy retatrutide near me
- how much does kerosene cost a gallon
- silicon tetrafluoride
- dienoget
- polypropylene index price
- skytrofa auto-injector
- amine oxides
- retatrutide peptide supplier
- dayquil ingredients vs nyquil
- retatrutide peptide supplier
- sds for sodium bicarbonate